Siddiqui Afzal A, Siddiqui Sabrina Z
Department of Internal Medicine, Center for Tropical Medicine and Infectious Diseases, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Department of Internal Medicine, Center for Tropical Medicine and Infectious Diseases, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Trends Parasitol. 2017 Mar;33(3):194-201. doi: 10.1016/j.pt.2016.10.010. Epub 2016 Nov 16.
Mass antiparasitic drug administration programs and other control strategies have made important contributions in reducing the global prevalence of helminths. Schistosomiasis, however, continues to spread to new geographic areas. The advent of a viable vaccine and its deployment, coupled with existing control efforts, is expected to make significant headway towards sustained schistosomiasis control. In 2016, Science ranked the schistosomiasis vaccine as one of the top 10 vaccines that needs to be urgently developed. A vaccine that is effective against geographically distinct forms of intestinal/hepatic and urinary disease is essential to make a meaningful impact in global reduction of the disease burden. In this opinion article, we focus on salient features of schistosomiasis vaccines in different phases of the clinical development pipeline and highlight the Sm-p80-based vaccine which is now being prepared for human clinical trials.
大规模抗寄生虫药物给药计划及其他控制策略在降低全球蠕虫感染率方面做出了重要贡献。然而，血吸虫病仍在向新的地理区域蔓延。一种可行疫苗的出现及其应用，再加上现有的控制措施，有望在持续控制血吸虫病方面取得重大进展。2016年，《科学》杂志将血吸虫病疫苗列为急需研发的十大疫苗之一。一种对肠道/肝脏和泌尿系统疾病的不同地理形式有效的疫苗对于在全球减轻疾病负担方面产生有意义的影响至关重要。在这篇观点文章中，我们重点关注处于临床开发不同阶段的血吸虫病疫苗的显著特征，并着重介绍目前正准备进行人体临床试验的基于Sm-p80的疫苗。
